Rakesh Jalali

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6450589/publications.pdf

Version: 2024-02-01

		331670	377865
84	1,392	21	34
papers	citations	h-index	g-index
100	100	100	1059
108	108	108	1958
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Clinical Audit of Survival Outcomes and Prognostic Factors in Adolescents and Adults with Medulloblastoma. Journal of Adolescent and Young Adult Oncology, 2022, 11, 68-77.	1.3	5
2	Prognostic impact of semantic MRI features on survival outcomes in molecularly subtyped medulloblastoma. Strahlentherapie Und Onkologie, 2022, 198, 291.	2.0	1
3	Omission of Upfront Craniospinal Irradiation in Patients with Low-Risk WNT-Pathway Medulloblastoma Is Associated with Unacceptably High Risk of Neuraxial Failure. Clinical Cancer Research, 2022, 28, 4180-4185.	7.0	12
4	Clinical approach to re-irradiation for recurrent diffuse intrinsic pontine glioma. Japanese Journal of Clinical Oncology, 2021, 51, 762-768.	1.3	8
5	Checkpoint inhibitors and radiotherapy in refractory malignant melanocytic schwannoma with Carney complex: first evidence of efficacy. BMJ Case Reports, 2021, 14, e240296.	0.5	4
6	Downregulation of ARID1B, a tumor suppressor in the WNT subgroup medulloblastoma, activates multiple oncogenic signaling pathways. Human Molecular Genetics, 2021, 30, 1721-1733.	2.9	8
7	MiR-592 activates the mTOR kinase, ERK1/ERK2 kinase signaling and imparts neuronal differentiation signature characteristic of Group 4 medulloblastoma. Human Molecular Genetics, 2021, 30, 2416-2428.	2.9	11
8	Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy. World Neurosurgery, 2021, 154, e176-e184.	1.3	1
9	TERT Promoter Mutation in Adult Glioblastomas: It's Correlation with Other Relevant Molecular Markers. Neurology India, 2021, 69, 126.	0.4	2
10	Safety and efficacy of bevacizumab biosimilar in recurrent/ progressive glioblastoma. Ecancermedicalscience, 2021, 15, 1166.	1.1	3
11	Pilot testing and vernacular translation of a questionnaire for assessment of satisfaction in patients on radiotherapy in India. Indian Journal of Cancer, 2021, 58, 573.	0.2	O
12	Cabergoline may act as a radioprotective agent in Cushing's disease. Clinical Endocrinology, 2020, 92, 55-62.	2.4	12
13	A comparison of long-term clinical outcomes of accelerated partial breast irradiation using interstitial brachytherapy as per GEC-ESTRO, ASTRO, updated ASTRO, and ABS guidelines. Brachytherapy, 2020, 19, 337-347.	0.5	5
14	Reverse swingâ€M, phase 1 study of repurposing mebendazole in recurrent highâ€grade glioma. Cancer Medicine, 2020, 9, 4676-4685.	2.8	16
15	Hippocampal radiotherapy dose constraints for predicting long-term neurocognitive outcomes: mature data from a prospective trial in young patients with brain tumors. Neuro-Oncology, 2020, 22, 1677-1685.	1.2	37
16	A randomized trial of stereotactic versus conventional radiotherapy in young patients with low-grade brain tumors: occupational therapy-based neurocognitive data. Neuro-Oncology Advances, 2020, 2, vdaa130.	0.7	4
17	Nomograms based on preoperative multiparametric magnetic resonance imaging for prediction of molecular subgrouping in medulloblastoma: results from a radiogenomics study of 111 patients. Neuro-Oncology, $2019, 21, 115-124$.	1.2	49
18	Pilocytic astrocytomas: BRAFV600E and BRAF fusion expression patterns in pediatric and adult age groups. Child's Nervous System, 2019, 35, 1525-1536.	1.1	17

#	Article	IF	Citations
19	Dose-Constraint Model to Predict Neuroendocrine Dysfunction in Young Patients With Brain Tumors: Data From a Prospective Study. Practical Radiation Oncology, 2019, 9, e362-e371.	2.1	3
20	Antiemetic prophylaxis with temozolomide: an audit from a tertiary care center. Neuro-Oncology Practice, 2019, 6, 479-483.	1.6	2
21	Downregulation of miR-204 expression defines a highly aggressive subset of Group 3/Group 4 medulloblastomas. Acta Neuropathologica Communications, 2019, 7, 52.	5.2	17
22	Utility of flouro-deoxy-glucose positron emission tomography/computed tomography in the diagnostic and staging evaluation of patients with primary CNS lymphoma. CNS Oncology, 2019, 8, CNS46.	3.0	18
23	A cross-sectional audit of distress in patients undergoing adjuvant therapy or follow-up in central nervous system malignancies. Neuro-Oncology Practice, 2019, 6, 305-310.	1.6	0
24	Primary pineal tumors – Unraveling histological challenges and certain clinical myths. Neurology India, 2019, 67, 491.	0.4	6
25	Distinct demographic profile and molecular markers of primary CNS tumor in 1873 adolescent and young adult patient population. Child's Nervous System, 2018, 34, 1489-1495.	1.1	3
26	Shadow study: randomized comparison of clinic with video follow-up in glioma undergoing adjuvant temozolomide therapy. CNS Oncology, 2018, 7, CNS14.	3.0	7
27	Impact of timing of radiation therapy on outcomes in atypical meningioma: A clinical audit. Practical Radiation Oncology, 2018, 8, e275-e284.	2.1	8
28	Global Cancer Clinical Trialsâ€"Cooperation Between Investigators in High-Income Countries and Lowand Middle-Income Countries. JAMA Oncology, 2018, 4, 765.	7.1	10
29	Impact of WHO 2016 update of brain tumor classification, molecular markers and clinical outcomes in pleomorphic xanthoastrocytoma. Journal of Neuro-Oncology, 2018, 136, 343-350.	2.9	26
30	LGG-08. PILOCYTIC ASTROCYTOMAS, EXHIBIT DIFFERENTIAL AGE-BASED PATTERNS OF BRAFV600E AND BRAF GENE FUSIONS ACROSS DIFFERENT LOCATIONS. Neuro-Oncology, 2018, 20, i105-i106.	1.2	0
31	DEV-11. OUTCOMES OF MALIGNANT BRAIN TUMORS IN YOUNG CHILDREN TREATED WITH CHEMOTHERAPY AND DELAYED RADIOTHERAPY IN A RESOURCE LIMITED SETTING. Neuro-Oncology, 2018, 20, i47-i47.	1.2	0
32	MBRS-41. DIFFERENTIAL microRNA EXPRESSION IN THE MOLECULAR SUBGROUPS OF MEDULLOBLASTOMAS: ROLE IN TUMOR BIOLOGY AND CLINICAL CHARACTERISTICS. Neuro-Oncology, 2018, 20, i137-i137.	1.2	0
33	EPEN-19. SUPRATENTORIAL EPENDYMOMAS - L1CAM EXPRESSION AND RELA FUSION, THEIR CORRELATION WITH CLINICOPATHOLOGICAL FEATURES. Neuro-Oncology, 2018, 20, i77-i77.	1.2	0
34	MGMT gene promoter methylation and its correlation with clinicopathological parameters in glioblastomas. Neurology India, 2018, 66, 1106.	0.4	10
35	Breast cancer in a tertiary cancer center in India - An audit, with outcome analysis. Indian Journal of Cancer, 2018, 55, 16.	0.2	29
36	Pediatric Glioma. Pediatric Oncology, 2018, , 171-202.	0.5	0

#	Article	IF	CITATIONS
37	Efficacy of Stereotactic Conformal Radiotherapy vs Conventional Radiotherapy on Benign and Low-Grade Brain Tumors. JAMA Oncology, 2017, 3, 1368.	7.1	59
38	Impact of adjuvant systemic chemotherapy on wound healing and cosmetic outcome in 224 women treated with accelerated partial breast irradiation using interstitial brachytherapy. Brachytherapy, 2017, 16, 935-942.	0.5	6
39	Restoration of miR-30a expression inhibits growth, tumorigenicity of medulloblastoma cells accompanied by autophagy inhibition. Biochemical and Biophysical Research Communications, 2017, 491, 946-952.	2.1	38
40	Long-term Survivors of Childhood Brain Tumors: Impact on General Health and Quality of Life. Current Neurology and Neuroscience Reports, 2017, 17, 99.	4.2	22
41	Patient survivorship and caregivers' needs in neuro-oncology practice: burden and novel interventions. Neuro-Oncology Practice, 2017, 4, 75-76.	1.6	O
42	SHADOW study: Comparison of conventional clinical follow-up with clinician led video follow-up in newly diagnosed patients with intermediate and high grade glioma receiving adjuvant temozolomide therapy Journal of Clinical Oncology, 2017, 35, 2024-2024.	1.6	1
43	Histological spectrum of oligodendroglial tumors: Only a subset shows $1p/19q$ codeletion. Neurology India, 2017, 65, 113.	0.4	7
44	Demographic profile, clinicopathological spectrum, and treatment outcomes of primary central nervous system tumors: Retrospective audit from an academic neuro-oncology unit. Indian Journal of Cancer, 2017, 54, 594.	0.2	5
45	Heterogeneous spectrum of childhood and adult SHH medulloblastoma: Clinical, radiogenomic features, patterns of failure and survival Journal of Clinical Oncology, 2017, 35, 2063-2063.	1.6	0
46	Intracranial germ cell tumors: a multi-institutional experience from three tertiary care centers in India. Child's Nervous System, 2016, 32, 2173-2180.	1.1	27
47	Neuro-Oncology Practice: old challenges, new insights. Neuro-Oncology Practice, 2016, 3, 69-70.	1.6	1
48	Clinical outcome and molecular characterization of pediatric glioblastoma treated with postoperative radiotherapy with concurrent and adjuvant temozolomide: a single institutional study of 66 children. Neuro-Oncology Practice, 2016, 3, 39-47.	1.6	6
49	Helical tomotherapy-based craniospinal irradiation: mature outcomes of a prospective feasibility study. Journal of Radiation Oncology, 2016, 5, 221-230.	0.7	1
50	Indian data on central nervous tumors: A summary of published work. South Asian Journal of Cancer, 2016, 05, 147-153.	0.6	49
51	MiR-148a, a microRNA upregulated in the WNT subgroup tumors, inhibits invasion and tumorigenic potential of medulloblastoma cells by targeting Neuropilin 1. Oncoscience, 2015, 2, 334-348.	2.2	32
52	IAEA randomised trial of optimal single dose radiotherapy in the treatment of painful bone metastases. Radiotherapy and Oncology, 2015, 116, 10-14.	0.6	22
53	Diversity of challenges in neuro-oncology: basic realities and new insights. Neuro-Oncology Practice, 2015, 2, 55-56.	1.6	0
54	International patterns of palliative care in neuro-oncology: a survey of physician members of the Asian Society for Neuro-Oncology, the European Association of Neuro-Oncology, and the Society for Neuro-Oncology. Neuro-Oncology Practice, 2015, 2, 62-69.	1.6	18

#	Article	IF	CITATIONS
55	Impact of oligodendroglial component in glioblastoma (GBM-O): Is the outcome favourable than glioblastoma?. Clinical Neurology and Neurosurgery, 2015, 135, 46-53.	1.4	8
56	Commentary on 19thannual scientific meeting of the Society for Neuro-Oncology. Indian Journal of Medical and Paediatric Oncology, 2015, 36, 63.	0.2	0
57	Clinical outcomes of prospectively treated 140 women with early stage breast cancer using accelerated partial breast irradiation with 3 dimensional computerized tomography based brachytherapy. Radiotherapy and Oncology, 2015, 115, 349-354.	0.6	24
58	Long term results of a prospective study of internal mammary chain (IMC) brachytherapy Journal of Clinical Oncology, 2015, 33, e12061-e12061.	1.6	1
59	Neuro-Oncology Practice: Consolidating A Good Beginning. Neuro-Oncology Practice, 2014, 1, 31-32.	1.6	1
60	Prospective longitudinal assessment of sensorineural hearing loss with hyperfractionated radiation therapy alone in patients with average-risk medulloblastoma. Neuro-Oncology Practice, 2014, 1, 86-93.	1.6	1
61	Encouraging efficacy of modern conformal fractionated radiotherapy in patients with uncured Cushing's disease. Pituitary, 2014, 17, 60-67.	2.9	18
62	Prospective assessment of neurocognitive outcomes in children and young adults with progressive/residual benign and low-grade brain tumors treated with high-precision conformal or conventional radiotherapy: Results of a randomized clinical trial Journal of Clinical Oncology, 2014, 32, 2035-2035.	1.6	1
63	Palliative care and quality of life in neuro-oncology. F1000prime Reports, 2014, 6, 71.	5.9	10
64	Real-time PCR assay based on the differential expression of microRNAs and protein-coding genes for molecular classification of formalin-fixed paraffin embedded medulloblastomas. Neuro-Oncology, 2013, 15, 1644-1651.	1.2	73
65	Can Multiparametric MRI and FDG-PET Predict Outcome in Diffuse Brainstem Glioma? A Report from a Prospective Phase-II Study. Pediatric Neurosurgery, 2013, 49, 274-281.	0.7	23
66	Factors influencing quality of life in adult patients with primary brain tumors. Neuro-Oncology, 2012, 14, iv8-iv16.	1.2	23
67	Hyperfractionated craniospinal re-irradiation for recurrent/progressive disseminated medulloblastoma using image-guided radiotherapy: leveraging radiobiology with technology. Journal of Radiation Oncology, 2012, 1, 87-92.	0.7	1
68	Prospective Evaluation of Radiotherapy With Concurrent and Adjuvant Temozolomide in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma. International Journal of Radiation Oncology Biology Physics, 2010, 77, 113-118.	0.8	90
69	Factors Influencing Neurocognitive Outcomes in Young Patients With Benign and Low-Grade Brain Tumors Treated With Stereotactic Conformal Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2010, 77, 974-979.	0.8	134
70	Is there a need to regulate health care advertisement for lay public?. Journal of Cancer Research and Therapeutics, 2010, 6, 131.	0.9	2
71	Curability of cancer by radiotherapy and chemotherapy, including in neuraxial neoplasms. Neurology India, 2009, 57, 13.	0.4	3
72	Factors influencing activities of daily living using FIM–FAM scoring system before starting adjuvant treatment in patients with brain tumors: results from a prospective study. Journal of Neuro-Oncology, 2009, 94, 103-110.	2.9	41

#	Article	IF	CITATIONS
73	Prospective assessment of quality of life in adult patients with primary brain tumors in routine neurooncology practice. Journal of Neuro-Oncology, 2009, 95, 413-419.	2.9	61
74	Micromultileaf collimator-based stereotactic radiosurgery for selected arteriovenous malformations: Technique and preliminary experience. Journal of Cancer Research and Therapeutics, 2009, 5, 186.	0.9	6
75	Prospective analysis of incidence of central nervous tumors presenting in a tertiary cancer hospital from India. Journal of Neuro-Oncology, 2008, 87, 111-114.	2.9	40
76	Prospective assessment of activities of daily living using Modified Barthel's Index in children and young adults with low-grade gliomas treated with stereotactic conformal radiotherapy. Journal of Neuro-Oncology, 2008, 90, 321-328.	2.9	19
77	Prospective evaluation of concomitant tumour bed boost with whole breast irradiation in patients with locally advanced breast cancer undergoing breast-conserving therapy. Breast, 2008, 17, 64-70.	2.2	13
78	Suprasellar ganglioglioma with unusual diffuse involvement of the entire optico-chiasmal hypothalamic pathway. Journal of Cancer Research and Therapeutics, 2008, 4, 140.	0.9	22
79	Techniques of tumour bed boost irradiation in breast conserving therapy: Current evidence and suggested guidelines. Acta Oncol \tilde{A}^3 gica, 2007, 46, 879-892.	1.8	39
80	Neuropsychological status in children and young adults with benign and low-grade brain tumors treated prospectively with focal stereotactic conformal radiotherapy. International Journal of Radiation Oncology Biology Physics, 2006, 66, S14-S19.	0.8	10
81	Translation and pilot validation of Hindi translation of assessing quality of life in patients with primary brain tumours using EORTC brain module (BN-20). Journal of Cancer Research and Therapeutics, 2006, 2, 166.	0.9	9
82	High precision conformal radiotherapy employing conservative margins in childhood benign and low-grade brain tumours. Radiotherapy and Oncology, 2005, 74, 37-44.	0.6	21
83	Transperineal Low-Dose Rate Iridium-192 Interstitial Brachytherapy in Cervical Carcinoma Stage IIB. Strahlentherapie Und Onkologie, 2001, 177, 517-524.	2.0	9
84	Optimization of stereotactically-guided conformal treatment planning of sellar and parasellar tumors, based on normal brain dose volume histograms. International Journal of Radiation Oncology Biology Physics, 1999, 45, 507-513.	0.8	57